SELECTIVE NOX-1 INHIBITOR PEPTIDES AND USES THEREOF

The present invention relates to novel peptides, compositions and methods for the prevention and/or treatment of pathological conditions and diseases associated with NADPH oxidase 1 (Nox1) activity, and/or increased reactive oxygen species (ROS) production. The novel peptides are thus particularly useful for treating and/or preventing cancer, atherosclerosis, angiogenesis, and aging. 122-. (canceled)23. A method of preventing and/or treating a pathological condition or disease associated with NADPH oxidase 1 (Nox1) activity and/or increased reactive oxygen species (ROS) production in a subject , comprising administering to said subject a therapeutically effective amount of a peptide having 7 to 35 amino acids and comprising the following sequence: X1 is A, P or Q', 'X2 is P, T, V, A, S, C, M or K', 'X3 is L, I, V or A, and', 'X4 is T, V, S, A or M., 'X1-P-X2-X3-P-X4-R (SEQ ID NO: 1), wherein'}24. The method of claim 23 , wherein said peptide comprises any of the sequences of PPTVPTR (SEQ ID NO: 2) claim 23 , PPSVPTR (SEQ ID NO: 3) claim 23 , PPMVPTR (SEQ ID NO: 4) claim 23 , PPCVPTR (SEQ ID NO: 5) claim 23 , PPPVPTR (SEQ ID NO: 6) claim 23 , PPAVPTR (SEQ ID NO: 7) claim 23 , PPVVPTR (SEQ ID NO: 8) claim 23 , PPTVPSR (SEQ ID NO: 9) claim 23 , PPTVPMR (SEQ ID NO: 10) claim 23 , PPTVPVR (SEQ ID NO: 11) claim 23 , PPTVPAR (SEQ ID NO: 12) claim 23 , QPTAPTR (SEQ ID NO: 13) claim 23 , PPTLPTR (SEQ ID NO: 14) claim 23 , PPTIPTR (SEQ ID NO: 15) claim 23 , PPTAPTR (SEQ ID NO: 16) claim 23 , PPKVPTR (SEQ ID NO: 17) claim 23 , QPTVPTR (SEQ ID NO: 18) claim 23 , or APTVPTR (SEQ ID NO: 19).25. The method of wherein said peptide is conjugated to a cell penetrating peptide or to an agent which increases the accumulation of said peptide in a cell claim 23 , via a covalent or non-covalent bond claim 23 , wherein optionally said cell penetrating peptide forms part of the sequence of the peptide.26Streptomyces hygroscopicus. The method of claim 25 , wherein said cell penetrating ...

USE OF A BETA BLOCKER FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HEMANGIOMAS

The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas. 119-. (canceled)20. A method for treating an infant or small child having an infantile hemangioma , the method comprising administering to the infant or small child a medicament comprising a pharmaceutically acceptable and efficient dose a beta blocker.21. The method of claim 20 , wherein the beta blocker is selected from the group consisting of non-selective beta blockers claim 20 , beta-1-selective beta blockers claim 20 , mixtures of alpha-1/beta-adrenergic antagonists claim 20 , beta-2-selective beta blockers claim 20 , and mixtures of two or more beta-blockers.22. The method of claim 20 , wherein the beta blocker is a non-selective beta blocker.23. The method of claim 20 , wherein the beta blocker is a beta-1 selective beta blocker.24. The method of claim 20 , wherein the beta blocker has an intrinsic sympathomimetic activity.25. The method of claim 20 , wherein the medicament is for oral or topical administration.26. A method for treating a hemangioma comprising administering to a patient in need thereof a pharmaceutically acceptable and efficient dose of a beta blocker.27. The method of claim 26 , wherein the beta blocker is selected from the group consisting of non-selective beta blockers claim 26 , beta-1-selective beta blockers claim 26 , mixtures of alpha-1/beta-adrenergic antagonists claim 26 , beta-2-selective beta blockers claim 26 , and mixtures of two or more beta-blockers.28. The method of claim 26 , wherein the beta blocker is a non-selective beta blocker.29. The method of claim 28 , wherein the non-selective beta blocker is selected from the ...

USE OF A BETA BLOCKER FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HEMANGIOMAS

The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas. 140-. (canceled)41. A method for treating a patient having a capillary or infantile hemangioma , comprising administering to the patient a pharmaceutically acceptable and efficient dose of a beta blocker.42. The method of claim 41 , wherein the beta blocker is selected from the group consisting of non-selective beta blockers claim 41 , beta-1-selective beta blockers claim 41 , mixtures of alpha-1/beta-adrenergic antagonists claim 41 , beta-2-selective beta blockers claim 41 , and mixtures of two or more beta-blockers.43. The method of claim 41 , wherein the beta blocker is a non-selective beta blocker.44. The method of claim 43 , wherein the non-selective beta blocker is selected from the group comprising alprenolol claim 43 , bucindolol claim 43 , carteolol claim 43 , carvedilol claim 43 , labetalol claim 43 , levobunolol claim 43 , medroxalol claim 43 , mepindolol claim 43 , metipranolol claim 43 , nadolol claim 43 , oxprenolol claim 43 , penbutolol claim 43 , pindolol claim 43 , propafenone claim 43 , propranolol claim 43 , sotalol claim 43 , timolol claim 43 , pharmaceutically acceptable salts thereof and mixtures thereof.45. The method of claim 41 , wherein the beta blocker is a beta-1 selective beta blocker.46. The method of claim 45 , wherein the beta-1 selective beta blocker is selected for example from the group comprising acebutolol claim 45 , atenolol claim 45 , betaxolol claim 45 , bisoprolol claim 45 , celiprolol claim 45 , esmolol claim 45 , metoprolol claim 45 , and nebivolol.47. The method of claim 41 , wherein the beta blocker has an intrinsic ...

SELECTIVE NOX-1 INHIBITOR PEPTIDES AND USES THEREOF

The present invention relates to novel peptides, compositions and methods for the prevention and/or treatment of pathological conditions and diseases associated with NADPH oxidase 1 (Nox1) activity, and/or increased reactive oxygen species (ROS) production. The novel peptides are thus particularly useful for treating and/or preventing cancer, atherosclerosis, angiogenesis, and aging. 122-. (canceled)23. A method of preventing and/or treating a pathological condition or disease associated with NADPH oxidase 1 (Nox1) activity and/or increased reactive oxygen species (ROS) production in a subject , comprising administering to said subject a therapeutically effective amount of a peptide having 7 to 35 amino acids and comprising the following sequence: X1 is A, P or Q', 'X2 is P, T, V, A, S, C, M or K', 'X3 is L, I, V or A, and', 'X4 is T, V, S, A or M., 'X1-P-X2-X3-P-X4-R (SEQ ID NO: 1), wherein'}24. The method of claim 23 , wherein said peptide comprises any of the sequences of PPTVPTR (SEQ ID NO: 2) claim 23 , PPSVPTR (SEQ ID NO: 3) claim 23 , PPTVPTR (SEQ ID NO: 4) claim 23 , PPTVPTR (SEQ ID NO: 5) claim 23 , PPPVPTR (SEQ ID NO: 6) claim 23 , PPTVPTR (SEQ ID NO: 7) claim 23 , PPTVPTR (SEQ ID NO: 8) claim 23 , PPTVPSR (SEQ ID NO: 9) claim 23 , PPTVPMR (SEQ ID NO: 10) claim 23 , PPTVPVR (SEQ ID NO: 11) claim 23 , PPTVPAR (SEQ ID NO: 12) claim 23 , QPTAPTR (SEQ ID NO: 13) claim 23 , PPTLPTR (SEQ ID NO: 14) claim 23 , PPTIPTR (SEQ ID NO: 15) claim 23 , PPTAPTR (SEQ ID NO: 16) claim 23 , PPKVPTR (SEQ ID NO: 17) claim 23 , QPTVPTR (SEQ ID NO: 18) claim 23 , or APTVPTR (SEQ ID NO: 19).25. The method of wherein said peptide is conjugated to a cell penetrating peptide or to an agent which increases the accumulation of said peptide in a cell claim 23 , via a covalent or non-covalent bond claim 23 , wherein optionally said cell penetrating peptide forms part of the sequence of the peptide.26Streptomyces hygroscopicus. The method of claim 25 , wherein said cell penetrating ...

SELECTIVE NOX-1 INHIBITOR PEPTIDES AND USES THEREOF

The present invention relates to novel peptides, compositions and methods for the prevention and/or treatment of pathological conditions and diseases associated with NADPH oxidase 1 (Nox1) activity, and/or increased reactive oxygen species (ROS) production. The novel peptides are thus particularly useful for treating and/or preventing cancer, atherosclerosis, angiogenesis, and aging. 133-. (canceled)35. The peptide of claim 34 , wherein said peptide has 100% sequence identity to any of SEQ ID NOs: 2-38.36. A composition comprising the peptide of .37. A pharmaceutical composition comprising the composition of and one or more pharmaceutically acceptable carrier(s).38. A method of decreasing the levels of reactive oxygen species (ROS) and/or inhibiting production of reactive oxygen species (ROS) claim 34 , and/or of selectively reducing and/or inhibiting NADPH oxidase 1 (Nox1) activity in a subject in need thereof claim 34 , comprising administering to the subject the peptide of .39. The method of claim 38 , wherein NADPH oxidase 1 (Nox1) activity selectively is reduced by at least 20% claim 38 , or at least 30% claim 38 , or at least 35% claim 38 , 40% claim 38 , 45% claim 38 , 50% claim 38 , 54% claim 38 , 55% claim 38 , 56% claim 38 , 57% claim 38 , 58% claim 38 , 59% claim 38 , 60% or 100%.40. A method for providing protection against UV-radiation or for enhancing photo protection to both UVA and UVB rays in a subject in need thereof claim 34 , comprising administering or applying to the skin of the subject an effective amount of the peptide of .41. A method of treating and/or repairing skin claim 34 , mucous membranes claim 34 , scalp and/or hair of a subject in need thereof claim 34 , comprising administering or applying to the skin of the subject the peptide of .42. A method of reducing or postponing skin conditions due to aging claim 34 , photo-aging claim 34 , and skin conditions due to premature aging in a subject in need thereof claim 34 , comprising ...

HANGING DEVICE FOR FOOTWALKING OR SCAFFOLDING

Multiple-use guardrail

This small post makes it possible, through a quick simple conversion without using a tool, to convert from a guardrail with a board to a guardrail with a barrier and vice versa. Its use also simplifies the fitting of guardrails along a non-planar surface. It has an immobilisation hook (2) (captive, orientable through 360@, and translatable along the axis of the small post) which is positioned on the upper transverse safety element which rests on the support closest to being in vertical alignment with the hook (2). The dual degree of freedom (rotation, translation) of the toe-board support (5) makes it possible to wedge a barrier (7) between the toe-board support (5) and the immobilisation hook (2) even along a non-planar surface. This small post is intended to equip guardrails on building sites using boards and/or barriers as transverse safety elements.

Fastening device for a service platform or facade scaffolding

The invention relates to the fastening of surface platforms or scaffolding against a facade shell of a building in the course of being erected. The fastening device 3 of the invention comprises a hook 8, a central body 9 which can be inserted into an orifice 11 of the facade shell, an articulated lever adjacent to the hook and making it possible to control the release of at least one bolt 12 behind the said shell. When the service platform is fastened, a crossmember 7 of the latter tilts the lever 10 and releases the bolt or bolts 12. Only one person is required to instal the fastening device 3, it being possible for this person to act on the lever 10 in order to partially release the bolt or bolts 12 waiting for the service platform to be fastened. Application in particular to the fastening of service platforms and supports for slip form or climbing form.

Selective Nox-1 inhibitor peptides and uses thereof

The present invention relates to novel peptides, compositions and methods for the prevention and/or treatment of pathological conditions and diseases associated with NADPH oxidase 1 (Nox1) activity, and/or increased reactive oxygen species (ROS) production. The novel peptides are thus particularly useful for treating and/or preventing cancer, atherosclerosis, angiogenesis, and aging.

MULTI-PURPOSE GUARDRAILS.

Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas

The present invention relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present invention provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.

Selective nox-1 inhibitor peptides and uses thereof

Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas

The present invention relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present invention provides an alternative to the known compounds, e.g. corticosteroïds, interferon or vincristine, generally used for the treatment of hemangiomas.

Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas

The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroïds, interferon or vincristine, generally used for the treatment of hemangiomas.

Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas

The present invention relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present invention provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.

Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas

Disclosed is the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas.

Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas

The present invention relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present invention provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.

Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas

The present invention relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present invention provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.

Verwendung eines betablockers zur herstellung eines arzneimittels zur behandlung von hämangiomen